Fondapar inux Versus Nadropar in for Prevention of Venous Thromboembol ism After Elect ive H ip and Knee Arthroplasty

Current Therapeutic Research - Clinical and Experimental

Volumn 74, Issue , 2013, Pages 49-53

  Argun, Mahmut ^a   Oner, Mithat ^a   Saglamoglu, Mehmet ^a   Karaman, Ibrahim ^a   Guney, Ahmet ^a   Halici, Mehmet ^a   Halil Kafadar, Ibrahim ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Arthroplasty; Fondaparinux; Nadroparin; Venous thromboembolism

Indexed keywords

ANTITHROMBIN III; FIBRINOGEN; FONDAPARINUX; NADROPARIN;

ADULT; ARTICLE; BIOCHEMISTRY; BLOOD CELL COUNT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIP ARTHROPLASTY; HUMAN; INTERNATIONAL NORMALIZED RATIO; KNEE ARTHROPLASTY; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; THROMBIN TIME; THROMBOPLASTIN TIME; VENOUS THROMBOEMBOLISM; VISUAL ANALOG SCALE;

EID: 84879453465     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2013.02.003     Document Type: Article

References (17)

1. Frostick S.P. Death after joint replacement. Haemostasis 2000, 30:84-87.
2. White R.H., Romano P.S., Zhou H., et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998, 158:1525-1531.
3. Nicolaides A.N. Prevention of venous thromboembolism: international consensus statement, guidelines compiled in accordance with the scientific evidence. Int Angiol 2001, 20:1-37.
4. McMillan W.D., McCarthy W.J., Lin S.J., et al. Perioperative low molecular weight heparin for infrageniculate bypass. J Vasc Surg 1997, 25:796-802.
5. Turpie A.G., Gallus A.S., Hoek J.A. Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001, 344:619-625.
6. Bauer K.A., Hawkins D.W., Peters P.C., et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents-the selective factor Xa inihibitors. Cardiovasc Drug Rev 2002, 20:37-45.
7. Yoo M.C., Kang C.S., Kim Y.H., Kim S.K. A prospective randomized study on the use of nadroparin calcium in the prophylaxis of thromboembolism in Korean patients undergoing elective total hip replacement. Intl Orthop 1997, 21:399-402.
8. Warwick D., Jeffrey H., David G., et al. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement: a prospective, randomized trial. J Bone Joint Surg 1998, 80:1158-1165.
9. Sikorski J.M., Hampson W.G., Staddon G.E. The natural history and aetiology of deep vein thrombosis after total hip replacement. J Bone Joint Surg Br 1981, 63-B:171-177.
10. Turpie A.G., Bauer K.A., Eriksson B.I., et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002, 162:1833-1840.
11. Pareint G.D., Wessinger S.J., Harris W.H. Survey of prophylaxis against venous thromboembolism in adults undergoing hip surgery. Clin Orthop 1987, 232:188-193.
12. Singelyn F.J., CPMC Verheyen, Piovella F., et al. The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: The EXPERT Study. Anesth Analg 2007, 105:1540-1547.
13. Bauer K.A., Eriksson B.I., Lassen M.R. Turpie AGG. No episode of thrombocytopenia after four-week administration of fondaparinux, a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRAPLUS study. J Thromb Haemos 2003, 1:2050.
14. Lassen M.R., Eriksson B.I. Absence of transaminase increase after four-week administration of fondaparinux (Arixtraw), a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study. J Thromb Haemos 2003, 1:2052.
15. Lensing A.W., Prins M.H., Davidson B.L., Hirsch J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995, 155:601-607.
16. Samama M. Contemporary laboratory monitoring of low molecular weight heparins. Thromb Haemost 1995, 15:119-123.
17. Fareed J., Jeske W., Hoppensteadt D., Clarizio R., Walenga J.M. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol 1998, 82:3-10.